This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.
Feasibility and acceptability of artemisinin-based combination therapy for the
home management of malaria in four African sites
Malaria Journal 2008, 7:6
Ikeoluwapo O Ajayi () Edmund N Browne () Bertha Garshong () Peter Agyei-Baffour Leticia Doamekpor () Andrew Balyeku () Kaendi Munguti () Article type
Article URL
This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below).
Articles in Malaria Journal are listed in PubMed and archived at PubMed Central.
For information about publishing your research in Malaria Journal or any BioMed Central journal, go For information about other BioMed Central publications go to 2008 Ajayi et al., licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2008 Ajayi et al., licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Feasibility and acceptability of artemisinin-based combination therapy for the
home management of malaria in four African sites
Ikeoluwapo O Ajayi*1, Edmund N Browne2, Bertha Garshong3, Fred Bateganya4, Bidemi Yusuf1, Peter Agyei-Baffour2, Leticia Doamekpor3, Andrew Balyeku4, Kaendi Munguti5, Simon Cousens6, Franco Pagnoni7 1 Malaria Research Laboratories, Institute of Medical Research and Training, College of Medicine, University of Ibadan, Nigeria 2 Department of Community Health, School of Medical Sciences, KNUST, Kumasi, 3 Health Research Unit, Ghana Health Service, Accra, Ghana 4 Department of Sociology, Makerere University, Kampala, Uganda 5 Institute for Development Studies, College of Humanities and Social Studies, University of Nairobi, Nairobi, Kenya 6 Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, UK 7Implementation Research & Methods Unit, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, * Corresponding author ENB: [email protected] FB: [email protected] AB: [email protected] FP: [email protected] The Home Management of Malaria (HMM) strategy was developed using chloroquine, a now obsolete drug, which has been replaced by artemisinin-based combination therapy (ACT) in health facility settings. Incorporation of ACT in HMM would greatly expand access to effective antimalarial therapy by the populations living in underserved areas in malaria endemic countries. The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated.
A multi-country study was performed in four district-size sites in Ghana (two sites), Nigeria and Uganda, with populations ranging between 38,000 and 60,000.
Community medicine distributors (CMDs) were trained in each village to dispense pre-packaged ACT to febrile children aged 6-59 months, after exclusion of danger signs. A community mobilization campaign accompanied the programme. Artesunate- amodiaquine (AA) was used in Ghana and artemether-lumefantrine (AL) in Nigeria and Uganda. Harmonized qualitative and quantitative data collection methods were used to evaluate CMD performance, caregiver adherence and treatment coverage of febrile children with ACTs obtained from CMDs.
Some 20,000 fever episodes in young children were treated with ACT by CMDs across the four study sites. Cross-sectional surveys identified 2,190 children with fever in the two preceding weeks, of whom 1,289 (59%) were reported to have received ACT from a CMD. Coverage varied from 52% in Nigeria to 75% in Ho District, Ghana. Coverage rates did not appear to vary greatly with the age of the child or with the educational level of the caregiver. A very high proportion of children were reported to have received the first dose on the day of onset or the next day in all four sites (range 86-97%, average 90%). The proportion of children correctly treated in terms of dose and duration was also high (range 79-97%, average 85%). Overall, the proportion of febrile children who received prompt treatment and the correct dose for the assigned duration of treatment ranged from 71% to 87% (average 76%). Almost all caregivers perceived ACT to be effective, and no severe adverse events were ACTs can be successfully integrated into the HMM strategy.
Home Management of Malaria (HMM) for children with uncomplicated malaria in high transmission areas in Africa is an integral part of malaria case management within the overall Roll Back Malaria (RBM) strategy [1]. If the Abuja target of 60% of uncomplicated malaria episodes receiving effective treatment within 24 hours [2] and the Millennium Development Targets 5, 8 and 17 (reducing childhood mortality, halting the increase in malaria incidence and providing access to affordable essential drugs in developing countries) [3] are to be met, there is an urgent need to increase access to effective malaria treatment at the community level, especially in underserved rural areas.
So far, 18 African countries have adopted HMM as part of their malaria control programme [4]. Due to unacceptable levels of resistance to chloroquine by Plasmodium falciparum, 44 countries in Africa have adopted artemisinin-based combination therapy (ACT) as the first line treatment for uncomplicated malaria [5].
However, in most cases, the deployment of ACT is currently limited to health facilities, with large scale implementation of HMM using ACT delayed by concerns about the use of ACT at the community level [6-8].
A major concern with using ACT at the community level is the potential for poor adherence to the treatment schedule by both caregivers and community medicine distributors (CMDs). This could facilitate the development of parasite resistance to these expensive but currently highly efficacious drugs. Other concerns relate to acceptability by the community, the incidence of adverse events, cost and ability to provide adequate storage conditions to ensure drug stability in the community.
A pilot study carried out in Ghana in 2004 [9] provided preliminary evidence for the feasibility and acceptability of the use of artemether-lumefantrine (AL) in the HMM context. However, this study was essentially a qualitative assessment of community acceptability. To provide additional evidence to support the use of ACT at the community level, the UNICEF-UNDP-WORLD BANK-WHO Special Programme for Research and Training in Tropical Diseases (TDR) funded four studies in sites in Ghana, Nigeria and Uganda, representing different health system and epidemiological settings. This paper reports on the feasibility, acceptability and utilization of ACT provided at the community level.
Study sites and population
This multi-country study was performed in Ghana (two sites), Nigeria and Uganda all in sub-Saharan Africa. In Ghana two districts, Ejisu-Juaben and Ho were studied and in Ho district, an urban and a rural site were studied. In Nigeria, two districts Badeku and Ojoku/Ajia in Ona-ara local government were studied. The sites in Ejisu-Juaben, Ghana; Ona-ara Local Government, Nigeria; and Buguri and Iganga districts, Uganda were all rural areas. Ghana and Nigeria are located in West Africa, while Uganda is in East Africa. Table 1 describes the location and population characteristics of the different study sites, details of the community-based medicine distributors (CMDs) deployed, their training and supervision processes, and type, dosing schedule and cost to the end user of the antimalarial drug used.
Study design
The study was conducted in three phases. The first phase involved advocacy, community mobilization, selection of CMDs and establishment of key baseline indicators. Information, Education and Communication (IEC) materials were developed and research staff recruited and trained. The intervention phase involved the training of CMDs and distribution of ACT. A year after commencement of ACT distribution, a household survey, interviewing eligible caregivers about child fevers in the past two weeks, was performed to evaluate the intervention.
Sample size
It was decided that to yield useful results in terms of feasibility, the study should cover populations with a minimum population of around 40,000 - the size of a typical district. The sample size for the household survey was calculated using country- specific fever prevalence rates to provide a precision of ±5% for the estimates of coverage of ACT treatment through CMDs, assuming a design effect of two. The minimum number of households to be interviewed ranged from 700 to 768.
Data collection methods
Qualitative and quantitative data collection methods were used. Data collection tools for all the sites were harmonized prior to the intervention with some country specific modifications. The tools included the survey questionnaire and focus group discussion (FGD) and key informant interview (KII) guides, which were pre-tested and translated into the local languages. The format of CMDs' registers was also harmonized. The household survey focused on the health-seeking behaviour of caregivers of children with fever in the preceding two weeks, with an emphasis on timeliness of treatment, compliance with the prescribed treatment course, and perceptions of effectiveness and drug related adverse events. The FGD and KII guides focused on health-seeking behaviours, beliefs about the aetiology of malaria, treatment practices and community perceptions of the intervention.
Community medicine distributors
Community medicine distributors were trusted members of the community who were chosen by the community from a range of backgrounds, including farmers, chemical/medicine sellers, teachers, traders, community health workers, artisans, ‘mother trainers', and opinion leaders (Table 1). In Ghana and Nigeria nurses and community health officers at first-level formal health facilities were counted as CMDs.
‘Mother trainers' were lay mothers who were selected from within the communities and trained to distribute drugs.
Selection criteria for CMDs included being a permanent resident (at least one year), trusted and respected by the community, able to keep simple records, and a willingness to serve. Uganda had a functioning pre-existing cadre of CMDs who were co-opted into the study. The number of CMDs per community depended on the community's population size. An average of two CMDs per community was used across the four sites (one CMD per 600 population).
Although CMDs were not paid a salary, various motivation mechanisms were used.
Some of these included rain coats, bicycles, boots, watches, T-shirts and certificates of participation. Quarterly monetary allowances varied between USD 4.5 (Uganda), USD 5 (Ejisu-Juaben) and USD 8 (Ho). In Nigeria, the CMDs received a commission of between USD 0.20 and USD 0.30 for each pack of AL dispensed in addition to periodic gifts and reimbursement of transportation fares.
Drugs used in the study
Two different ACTs were used in accordance with the national drug policies of the participating countries; AL was used in Uganda and Nigeria, and artesunate- amodiaquine (AS/AQ) was used in Ghana.
For the AS/AQ combination, blister packs containing co-packed artesunate and amodiaquine tablets of 50 and 153 mgs respectively were used. For children aged 12 to 59 months the recommended dose of AS/AQ was one tablet of each drug once per day. However, for children of six to 11 months of age, tablets had to be broken in half and repackaged to comply with the recommended AS/AQ dose in that age group.
In Nigeria and Uganda, a fixed combination of 20 mg of artemether and 120 mg of lumefantrine (AL) in two types of blister pack, one for children below three years of age and another for children three years and above, were used. The recommended dose for children aged six to 35 months was one tablet twice daily for three days, and for children aged 36 to 59 months two tablets twice daily for three days. Caregivers were advised to administer the drug after meals, preferably fatty food.
Drug supply
In all the sites, drugs were provided through existing public health structures, at health district or sub-district level. In general, the distribution points for drugs were the local health facilities. In Uganda, CMDs replenished their stock at monthly meetings at health facility level. In Nigeria and Ghana, CMDs replenished their stocks from the health facilities as the need arose. In some instances drugs were delivered by the research team or by health staff during supervisory visits.
Monthly supervision was undertaken in all sites, by health staff or by the research team (Table 1). In each site, supervision included checking drug stocks, their storage conditions, and the CMDs' registers. The research team provided fuel and travel allowances to supervisors. In Nigeria, unscheduled inspections were periodically EPI info version 6.02, SPSS version 11.0 and STATA version 9.2 were used by the four sites to enter and analyse data. A set of indicators and quantitative analyses to be performed were agreed in discussion with research staff from each site. Each research team then undertook the analysis of their own data using standard statistical methods.
The FGD and KII information was transcribed and content analysis performed. From the transcripts and field notes, the responses to questions asked to explore issues of interest were grouped together, coded, categorized and analysed according to emerging themes. The findings were interpreted and reported in the form of narratives.
Ethical approval for conduct of this study was obtained from the WHO Ethics Review Committee and at national level from the appropriate Ethical Review Boards.
Informed consent was obtained from community heads, household heads and the caregivers who participated in the study.
Utilization of CMDs
Based on the records maintained by the CMDs, some 20,000 fever episodes in young children were treated with ACTs by CMDs across the four study sites (Table 2). The total number of episodes treated varied considerably between sites as did the average number of episodes treated per CMD (from 17 per CMD in Nigeria to 93 in Uganda).
The higher number of episodes treated in Uganda may be explained by the fact that home-based management of fevers has been implemented there since 2001. A higher attrition rate of CMDs in Nigeria compared to other study sites may also have contributed to the lower figures recorded there. Slightly more girls (4,928) than boys (4,595) were treated across the three sites in which this information was recorded. In this study, the accurate population denominators were not available. However, taking into account the width of the age groups, utilization appeared to decline somewhat with age (from 3,571 children in the 6-month age band from 6-11 months to 6,627 children in the two year age band from 36-59 months). Utilization was generally prompt with at least half of all children presenting on the day of onset or within 24 hours of onset in all four sites. In the three sites which recorded promptness as "same day" or "next day" 73-90% of children presented on the day of onset or the next day.
Treatment coverage of febrile episodes by CMDs
Data from the community-based cross-sectional surveys were used to estimate the proportion of febrile children receiving ACT from CMDs. A total of 2,190 children with fever in the two weeks preceding the survey were identified of whom 1,289 (59%) were reported to have received ACT from a CMD (Table 3). Coverage varied from 52% in Nigeria to 75% in Ho District, Ghana (P<0.001). Coverage rates did not appear to vary greatly with age, except perhaps in Ejisu-Juaben District, Ghana, where coverage appeared lower in the six to 11 months age group than in older age groups (Table 3). Overall, across the four sites, treatment coverage did not appear to vary strongly with the educational level of the caregiver.
Based on the information recorded by the CMDs in their registers, a very high proportion of children received the correct dose of ACTs (97% or greater in all sites; Table 4). From the survey data, CMDs were reported to have explained the dosing schedule on a very high proportion of occasions (>90% in all sites), but performed less well with respect to explaining danger signs or possible adverse events (Table 4).
This was particularly pronounced in Ejisu-Juaben District in Ghana. Availability of CMDs was reported to be good, with 85% or more of caretakers reporting that they found the CMD at the first time of visiting.
A young woman in Nigeria said: ‘CMDs are always available. It is good we have two in our community, when one is out the village the other one attends to caregivers'. In two of the four sites there was some turnover of CMDs but the attrition rate in these sites was relatively low. The need for incentives for CMDs, however, was often mentioned as an issue. An opinion leader in Ho, Ghana, said: There is this saying that "the one who feeds a child will surely put her hands in her mouth"; our volunteers should be appreciated so that they can enjoy the work they are doing. For this, the community and I will think about it and compensate them by giving some allowance because sometimes they have to go and call them from wherever they are. From the survey data, a very high proportion of children were reported to have been treated promptly in all four sites (Table 5). The proportion of febrile children who received prompt treatment and received the correct dose for the assigned duration of treatment ranged from 71% in Uganda to 87% in Ghana (P<0.001; Table 5).
Adherence by caregivers was linked to better treatment outcome. A woman participating in a FGD in Ejisu-Juaben district said: "When I went in for the drug he gave me instructions on how to give the drug to the child. I was told to give it to him continuously for three days – two tablets (white & yellow) each day. I did that and afterwards the child was well again. Happiness was then restored in my home". A local council chairperson of Bwalula village in Uganda explained: From 1- 2 weeks during Homapak, it now takes about three months before my child gets sick. It is better than CQ when you complete the dose. Safety and perceived effectiveness of ACTs
The proportion of children for whom an adverse event was reported to the CMD was low (circa 1%) in both sites in which this information was available (Table 6). At the survey the proportion of children reported to have experienced an adverse event following treatment with ACT was somewhat higher (4-8%) but none of these adverse events were reported to be serious. In all sites almost all caretakers perceived ACT to be effective. In Ho, Ghana, a community member argued that: "The change is that, previously, when children fall sick, we take some time to look for money and walk all the distance to go to the hospital. Sometimes before we get there the child's condition becomes worse. If you are lucky to get to the hospital early, after treatment you walk the same distance back or referred to the big hospital. The unlucky ones either die before they get to the clinic or die at the clinic; but ever since the introduction of this program, we have seen a change. For a year now, since the introduction of the new drug, no child has died and we have not sent any of them to the hospital". A caregiver added: "As for the drug, it works like magic!" There are two major findings from this study. First, it showed, at a larger scale than previously [9], that making ACT available at the community level through trained CMDs results in a high degree of adherence by sensitized caregivers. Second, that community-based strategy can deliver high coverage of febrile episodes in children with prompt and adequate treatment. Importantly, these findings are consistent in four different sites in sub-Saharan Africa, both in West and East Africa.
There was high utilization of CMDs. In an estimated population of children aged 6 to 59 months across the sites of 27,450, the CMDs treated 20,563 episodes of fever during the year of implementation (0.75 episodes of fever per child on average)). This contrasts with the figure of 0.12- 0.34 episodes per year reported from African health facilities in available literature [10]. Furthermore, the majority of caregivers reported that CMDs were available at the first time of asking, and very little attrition of CMDs was reported. This demonstrates the potential of CMDs to increase access to care in underserved rural areas in Africa, where government health facilities are often under- utilized [11,12]. While every effort was made to ensure the implementation of the study as close as possible to real life conditions, its short duration and the research setting are likely to have contributed to the low attrition rate of CMDs observed in this study. Indeed, the need to provide CMDs with incentives was repeatedly mentioned in interviews and FGDs, and financial motivation is known to be a key factor determining long term performance of CMDs [13]. It is clear that this need must be addressed to ensure the long-term sustainability of CMDs performance.
Concerns have been raised by several authors about the potential misuse of ACT when deployed beyond the health system [6,7], which could lead to wastage of resources and the development of resistance to ACT. However, our findings indicate that there was appropriate prescription in terms of dose by CMDs and correct use by caregivers. In all study sites, 97% or more of the CMDs prescribed the correct dose of ACTs, and almost all of them explained the treatment schedule to the caregiver. Drug storage conditions were satisfactory in all sites.
These studies were designed for the CMDs to provide treatment on the basis of a clinical diagnosis. The possibility of moving away from a symptom based treatment to more complex therapeutic protocols based on parasitological confirmation is currently being investigated. To bring parasitological diagnosis to the community level will require reliable diagnostic tools, and evidence of feasibility and acceptability by the Adherence to the full treatment course has been highlighted as a matter of concern [14-16]. AL has to be taken twice a day for three days (one or two tablets depending on the age group), AS/AQ once daily for three days but two different tablets (or half tablets) each time. Both of these regimens are different from those for older antimalarials like chloroquine or sulphadoxine-pyrimethamine (SP). Nonetheless, reported adherence by caregivers to the correct treatment schedule in terms of dose and duration was high for both treatment regimes in all sites, ranging from 79% in Uganda to 97% in Ejisu, Ghana (85% on average across the sites). These findings are reassuring with regard to the potential for development of resistance, as exposure to sub-therapeutic drug levels is known to be a major factor in the selection of resistant parasites [17].
Furthermore, the majority of caregivers obtaining ACT from a CMD reported that they treated their children promptly (ranging from 86% to 97%, 90% on average across the sites, Table 5). Data from CMDs' registers (Table 2) support this finding, albeit with slightly lower proportions of children recorded to be treated on the day of onset or the next day in three sites. In Uganda, CMDs reported treating only half of the episodes within 24 hours, a proportion which is still substantially higher than previously reported by Nsungwa-Sabiiti [16]. The design of this study does not provide robust data on pharmacovigilance. However, both CMDs and caregivers report a very low incidence of adverse drug effects, none of which were reported to be Access to prompt and effective treatment is a cornerstone of the current malaria control strategy [18]. Several strategies have been developed to address the issue of access to antimalarials in Africa, including home management of malaria [1], improving the services of private medicine sellers [19], a set of integrated interventions including social marketing approaches [20] and improving the quality of health service performance [21]. Our study provides evidence that once the option of treating children with effective antimalarials close to home is made available to caregivers, a majority of them (ranging from 52% in Nigeria to 75% in Ho, Ghana) make use of it, in most cases in an appropriate and timely manner. This option should be regarded as a complementary to, rather than competing with, health facility delivery of care. As highlighted by Unger et al [21], interventions aiming at improving use rates of general health services have also a high potential of increasing malaria cure rates.
Overall effectiveness of drugs distributed at the community level is known to be influenced by several factors [16,22,23], not all of them addressed in this study.
However, the high level of correct prescription by CMDs, the promptness of treatment seeking and adherence to the treatment schedule by caregivers, and the coverage (59% on average across the sites) achieved in this study show that some key factors determining the effectiveness of antimalarial treatment can be successfully addressed.
Thus, this approach has great potential to contribute to reaching the Abuja target that "at least 60% of those suffering from malaria have prompt access to, and are able to correctly use, affordable and appropriate treatment within 24 hours of the onset of Previous studies have shown that use of the correct dose of chloroquine in uncomplicated malaria correlates with improvements in clinical condition [24], and that HMM with chloroquine has been effective in reducing both mortality[25] and severe malaria morbidity [26]. Studies in Uganda and Tanzania [27,28] have recently shown that the high parasitological cure rate of AL is not affected by unsupervised administration under routine clinical practice. A sub-study evaluating parasitological efficacy of the ACTs used in this study is being undertaken and will be reported on This study shows that ACT use can be successfully integrated in the HMM strategy.
While further studies are necessary to develop mechanisms for ensuring long-term performance of CMDs and to evaluate the effectiveness and safety of ACTs used within the context of HMM programmes, the findings of this study provide evidence to support scaling-up implementation of HMM with ACTs.
The authors declare that they have no competing interests.
All the authors except SC conceived the study; IA, ENB, BG and FB were principal investigators for their respective country's study site and together with FP, LD, BY and AB participated in the research designed and supervised data collection from the field. BY, PAB and SC performed most of the quantitative data analysis while KM analysed the qualitative data. FP, the WHO/TDR HMM research program manager monitored the four sites. All authors contributed to the draft. All authors read and approved the final manuscript.
The authors acknowledge the immense role of the community members, opinion leaders, CMDs, the health workers, research assistants, field supervisors and workers in Ejisu - Juaben and Ho district, Ghana, Ona-ara Local Government, Nigeria and Bugiri and Iganga Districts, Uganda.
We also acknowledge the valuable contribution of Dr. Josephine Namboze (WHO/AFRO) and Wilson Were (WHO/GMP) who facilitated the protocol development workshops. This investigation received technical and financial support from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.
1. World Health Organization: The Roll Back Malaria Strategy for Improving
Access to Treatment through Home Management of malaria.
2. World Health Organization: The African Summit on Roll Back Malaria, Abuja,
Nigeria. 25 April 2000. Geneva. WHO/CDS/RBM/2000.17.
3. Millennium goals: accessed 20 August 2007.
4. World Health Organization: WHO Global Malaria Programme, personal communication, August 2007.
5. World Health Organization: WHO Global Malaria Programme, personal communication, August 2007.
6. Charlwood D: The paradox of home management of malaria with artemisinin
combinations. Trends Parasitol 2004, 20: 405-406.
7. D'Alessandro U, Talisuna A, Boelaert M: Should artemisinin-based combination
treatment be used in the home-based management of malaria? Trop Med Int
Health 2005, 10: 1-2.
8. Pagnoni F, Kengeya-Kayondo J, Ridley R: Artemisinin-based combination
treatment in home-based management of malaria. Trop Med Int Health 2005, 10:
9. Chinbuah MA, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M: Feasibility
and Acceptability of the use of artemether-lumefantrine in the Home-
management of uncomplicated malaria in children 6-59 months old in Ghana.
Trop Med Int Health 2006, 11: 1003-1016.
10. Levy-Bruhl D, Soucat A, Osseni R, Ndiaye JM, Dieng B, De Bethune X, Diallo AT, Conde M, Cisse M, Moussa y, Drame K, Knippenberg R: The Bamako
Initiative in Benin and Guinea: improving the effectiveness of primary health
care. Int J Health Plann Manag1997, Suppl.1, S49-S79.
11. Mutabingwa TK: Artemisinin-based combination therapies (ACTs): Best hope
for malaria treatment but inaccessible to the needy! Acta Trop 2005, 95: 305–315.
12. Breman JG, Alilio RS, Mills A: Conquering the Intolerable Burden of Malaria:
What's new, what's needed: a summary. Am J Trop Med Hyg 2004, Suppl 2: 1–
13. Batega DW, Greer GJ, Plowman BA: Home-based management of fever
strategy in Uganda: Assessment of implementation and operation at district and
community levels.: Ministry of Health Uganda, the World Health Organization, and
BASICS II for the United States Agency for International Development 2004.
Arlington, Va.
14. McCombie SC: Self-treatment for malaria: the evidence and methodological
issues. Health Policy Plan 2002, 17: 333-344
15. Yeung S, White NJ: How do patients use antimalarial drugs? A review of the
evidence. Trop Med Int Health 2005, 10: 121-138.
16. Nsungwa-Sabiiti J, Tomson G, Pariyo G, Ogwal-Okeng J, Peterson S: Community effectiveness of malaria treatment in Uganda—a long way to Abuja
targets. Ann Trop Paed 2005, 25: 91-100.
17. White NJ: Antimalarial drug resistance. J. Clin. Invest. 2004, 113:1084-1092.
18. World Health Organization / UNICEF Africa malaria report 2003. WHO, Geneva, 19. Abuya TO, Mutemi W, Karisa B, Ochola SA, Fegan G, Marsh V: Use of over-
the-counter malaria medicines in children and adults in three districts in Kenya:
implications for private medicine retailer interventions. Malar J 2007, 6:57
20. Hetzel MW, Iteba N, Makemba A, Mshana C, Lengeler C, Obrist B, Schulze A, Nathan R, Dillip A, Alba S, Mayumana I, Khatib RA, Njau JD, Mshinda H: Understanding and improving access to prompt and effective malaria treatment
and care in rural Tanzania: the ACCESS Programme Malar J 2007, 6:83
21. Unger J-P, d'Alessandro U, De Paepe P, Green A: Can malaria be controlled
where basic health services are not used? Trop Med Int Health 2006, 11: 314-322.
22. Krause G, Sauerborn R: Comprehensive community effectiveness of health
care. A study of malaria treatment in children and adults in rural Burkina Faso.
Ann Trop Paed 2000, 20, 273-282.
23. Mueller O, Razum O, Traore C, Kouyate B: Community effectiveness of
chloroquine and traditional remedies in the treatment of young children with
falciparum malaria in rural Burkina Faso. Malar J 2004, 3:36 doi:10.1186/1475-
24. Okonkwo PO, Akpala CO, Okafor HU, Mbah AU, Nwaiwu O. Compliance to
correct dose of chloroquine in uncomplicated malaria correlates with
improvement in the condition of rural Nigerian children. Trans R Soc Trop Med
Hyg 2001, 95: 320-324.
25. Kidane G, Morrow RH:Teaching mothers to provide home management of
malaria in Tigray, Ethopia: a randomized trial. Lancet 2000, 356: 550-55.
26. Sirima SB, Konaté A, Tiono AB, Convelbo, Cousens S, Pagnoni F: Early
treatment of childhood fevers with pre-packed antimalarial drugs in the home
reduces severe malaria morbidity in Burkina Faso. Trop Med Int Health 2003, 8:
27. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J,Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for
treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomised trial. Lancet 2005, 365: 1467–1473.
28. Mutabingwa TK, Anthony D, Heller A, Hallett , Ahmed J, Drakeley C, Greenwood BM, Whitty CJM: Amodiaquine alone,
artemether-lumefantrine for outpatient treatment of malaria in Tanzanian
children: a four-arm randomised effectiveness trial. Lancet 2005, 365: 1474–1480.
Description of study sites and intervention implementation in four sites evaluating home management of malaria with artemisinin combination therapy Ejisu - Juaben District, Ghana Ho District, Ghana Badeku and Ojoku/Ajia Districts, Bugiri and Iganga Districts, Uganda 35 rural communities 40 rural communities 56 rural communities Population c. 38,000 Population 43,000 Population c. 60,000 Perennial malaria transmission Population c. 42,000 Perennial, hyperendemic malaria Perennial, hyperendemic transmission Perennial malaria 54 (51 male) trusted members of 76 (48 male) trusted 60 (4 male) including drug sellers, 118 (62 male) pre-existing cadre of CMDs community (farmers, teachers, drug members of community health workers and mothers chosen (chosen by the community) sellers), chosen by the community (farmers, teachers, drug by the communities sellers), chosen by the 5 days of training 2 days of training 2 days of training 2 days of training Provided with bicycles, boots & Provided with T-shirts, Received commission of 20-30 US Transport refund of USD 1.16 per meeting.
watches, raincoats, torches cents per pack distributed. Provided T-shirts, baseball caps, certificates with T-shirts, transport reimbursement, Festivity gift, and Bimonthly supervision by research Monthly supervision by Monthly supervision by research Monthly supervision by health staff staff; Monthly supervision by health staff and quarterly community Health Officers CMDs were not obliged to follow up caregivers. However, some of No active follow-up of caregivers Program ran within existing home them followed up and some gave drugs under direct observation.
management system. CMDs actively followed up treated children to establish treatment outcome Artesunate+Amodiaquine (ASAQ) once daily for 3 days Artemether-lumefantrine (Coartem®) twice daily for 3 days 2 types of blister pack, for children < 1year and children 1 year and 2 types of blister pack, for children < 3years and children 3 years and above 10 US cents for <1 year 20 US cents for < 3 years 20 US cents for 1 year and above 30 US cents for 3 years and above Charged for first 6 months only, Utilization of CMDs for treatment of children with fever in 4 sites (source: CMD registers) Bugiri and Iganga Districts, Uganda Districts, Nigeria Total number febrile episodes in children less than 5 treated with ACTs Number (%) treated by age Number (%) treated by sex Number (%) treated by promptness of utilization 5445 (49%) within Later than next day Treatment coverage of febrile children aged 6-59 months with ACTs obtained from CMDs (source: household survey) Districts, Nigeria Number treated (% coverage) by age in months Number treated (% coverage) by sex Number treated (%) coverage by educational level of caregiver Number treated (% coverage) by marital status of caregiver Measures of CMD performance in delivering ACTs in 4 sites (source: CMD registers + household survey) Correctness of prescription (from CMD register) receiving an over Number (%) of occasions on which CMD explained (from survey): Availability of CMDs (from survey) Storage of ACTs (from supervision records) supervisory visits Attrition of CMDs Adherence of caregivers to treatment schedule Number of episodes treated with ACTs children correctly treated (dose and promptly (receiving first dose on the same Safety and perceived effectiveness of treatment of ACTs obtained from Number of episodes treated with ACTs children reporting an adverse event to a Number (%) children reported recovered Number of episodes treated with ACTs children reporting an Number (%) children reported recovered Number of caregivers (%) who perceived


If the patient is not agitated, cyanosed nor imminently dying, a trial of methylphenidate dextroamphetamine Delirium and (Dexedrine®) 2.5–5.0mg once or twice daily in the morning may help. Tolerance develops to these drugs and may limit their role. A newer CNS stimulant, modafinil (Alertec®) may be tried. Its mechanism of action is not entirely

PROJECT AGREEMENT FOR THE QUEBEC LITHIUM SPODUMENE MINE IN PREAMBLE WHEREAS the Government of Canada is committed to improving the efficiency of the federal environmental assessment (EA) and regulatory review processes for major resource projects to enable a more effective assessment and mitigation of potential environmental effects, while protecting the health and safety of Canadians and promoting innovation and competitiveness within the Canadian resource industry sectors; AND WHEREAS the Government of Canada is committed to undertaking a process of early, effective and meaningful consultation with Aboriginal groups, including Treaty First Nations, Non-Treaty First Nations, Métis and Inuit people, concerning contemplated federal Crown (Crown) conduct with respect to, among other things, major resource projects that may adversely affect established or potential Aboriginal and treaty rights under Section 35 of the Constitution Act, 1982; AND WHEREAS the Government of Canada has created the Major Projects Management Office (MPMO) for the purpose of overseeing and tracking the federal review, which includes the EA, regulatory reviews and Aboriginal consultation activities for major resource projects; AND WHEREAS Quebec Lithium Inc. (the Proponent) has submitted a project description in support of its proposed 3,800 tonnes per day open-pit spodumene mine located about 60 km north of Val-d'Or, 38 km south-east of Amos and 15 km south-west of Barraute, Quebec; AND WHEREAS the Canadian Environmental Assessment Agency (CEA Agency) has commenced a comprehensive study pursuant to the former Canadian Environmental Assessment Act (CEAA)1; AND WHEREAS the CEA Agency and Fisheries and Oceans Canada (DFO) have regulatory and statutory duties in relation to the proposed project; AND WHEREAS nothing in this Project Agreement (the Agreement) fetters the powers, statutory authorities and functions of federal departments/agencies and their respective Ministers; NOW THEREFORE the signatories (the Parties) to this Agreement commit to work together to facilitate an effective, accountable, transparent, timely and predictable federal review in relation to the proposed project and to contribute to fulfilling the Crown's duty to consult with Aboriginal groups.